var data={"title":"Albumin solution: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Albumin solution: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5576?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=albumin-solution-patient-drug-information\" class=\"drug drug_patient\">see &quot;Albumin solution: Patient drug information&quot;</a> and <a href=\"topic.htm?path=albumin-solution-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Albumin solution: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130903\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Albuked 25;</li>\n      <li>Albuked 5;</li>\n      <li>Albumin-ZLB;</li>\n      <li>Albuminar-25;</li>\n      <li>Albuminar-5;</li>\n      <li>AlbuRx;</li>\n      <li>Albutein;</li>\n      <li>Buminate;</li>\n      <li>Flexbumin;</li>\n      <li>Human Albumin Grifols;</li>\n      <li>Kedbumin;</li>\n      <li>Plasbumin-25;</li>\n      <li>Plasbumin-5</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130904\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Alburex-25;</li>\n      <li>Alburex-5;</li>\n      <li>Albutein 25%;</li>\n      <li>Albutein 5%;</li>\n      <li>Octalbin 25%;</li>\n      <li>Octalbin 5%;</li>\n      <li>Plasbumin-25;</li>\n      <li>Plasbumin-5</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130921\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Blood Product Derivative;</li>\n      <li>\n        Plasma Volume Expander, Colloid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130906\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Use <b>5%</b> solution in hypovolemic patients or intravascularly-depleted patients. Use <b>25%</b> solution in patients in whom fluid and sodium intake is restricted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dose:</b> IV: 25 g; initial dose may be repeated in 15 to 30 minutes if response is inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adult respiratory distress syndrome:</b> IV: 25 g over 30 minutes (in combination with furosemide); may repeat at 8 hours (if necessary) for 3 days; titrate to fluid loss and normalization of serum total protein. Patients enrolled into the clinical trial had hypoproteinemia (total protein &lt;6 g/dL) (Martin 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypovolemia:</b> 5% albumin: IV: Initial: 12.5 to 25 g (250 to 500 mL); repeat after 15 to 30 minutes as needed (if hemodynamic stability is not achieved). <b>Note:</b> May be considered after inadequate response to crystalloid therapy and when nonprotein colloids are contraindicated. The volume administered and the speed of infusion should be adapted to individual response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Large-volume paracentesis:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> 25% albumin: 8 g for every liter removed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate recommendations:</i> 25% albumin: 5 to 10 g for every liter removed (usual dose cited: 8 g for every liter removed) (Bernardi 2012; Moore 2003; AASLD [Runyon 2012]) <b>or</b> 50 g total for paracentesis &gt;5 L (ATS 2004). <b>Note:</b> Administer soon after the procedure to avoid postprocedural complications (eg, hypovolemia, hyponatremia, renal impairment) (Moore, 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian hyperstimulation syndrome (treatment):</b> 25% albumin: IV: 50 to 100 g over 4 hours; repeat at 4 to 12 hours intervals as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plasma exchange:</b> 5% albumin: IV: Titrate dose to plasma volume removed during procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Spontaneous bacterial peritonitis (treatment) (off-label use):</b> 25% albumin: IV: Initial: 1.5 g/kg within 6 hours of diagnosis (in conjunction with appropriate antimicrobial therapy), followed by 1 g/kg on day 3 (Abd 2012; AASLD [Runyon 2012]; Sort 1999). <b>Note:</b> Clinical trials used albumin 20%; the difference in concentration compared with 25% albumin is deemed to be clinically inconsequential.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130915\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=albumin-solution-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Albumin solution: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">\n      <b>Note:</b> <b>5%</b> should be used in hypovolemic patients or intravascularly-depleted patients. <b>25%</b> should be used in patients in whom fluid and sodium intake must be minimized.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Hemolytic disease of the newborn:</b> Infants: IV: 1 g/kg/dose of 25% albumin prior to or during exchange transfusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Hypovolemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Infants and Younger Children: IV: 0.5 to 1 g/kg/dose (10 to 20 mL/kg/dose of albumin 5%); repeat in 30 minute intervals as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Older Children and Adolescents: IV: 12.5 to 25 g (250 to 500 mL of albumin 5%); repeat in 30 minute intervals as needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130907\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671332\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671333\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130890\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albumin-ZLB: 5% (250 mL, 500 mL); 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albuminar-5: 5% (250 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albuminar-25: 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albutein: 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Buminate: 5% (250 mL, 500 mL); 25% (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plasbumin-5: 5% (50 mL, 250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plasbumin-25: 25% (20 mL, 50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5% (50 mL [DSC]); 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albuked 5: 5% (250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albuked 25: 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AlbuRx: 5% (250 mL, 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albutein: 5% (50 mL, 250 mL, 500 mL); 25% (20 mL, 50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flexbumin: 5% (250 mL); 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Human Albumin Grifols: 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kedbumin: 25% (50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plasbumin-5: 5% (50 mL, 250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plasbumin-25: 25% (20 mL, 50 mL, 100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5% (100 mL, 250 mL, 500 mL); 25% (50 mL, 100 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130876\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130892\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For IV administration only. Infusion rate depends on indication and clinical situation. In emergencies, may administer as rapidly as necessary to improve clinical condition. After initial volume replacement: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5%: Do not exceed 2 to 4 mL/minute in patients with normal plasma volume; 5 to 10 mL/minute in patients with hypoproteinemia </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25%: Do not exceed 1 mL/minute in patients with normal plasma volume; 2 to 3 mL/minute in patients with hypoproteinemia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Rapid infusion may cause vascular overload. Albumin 25% may be given undiluted or diluted in normal saline. May give in combination or through the same administration set as saline or carbohydrates. Warm to room temperature before use if large volumes are administered. Use within 4 hours after entering package; discard unused portion. Some products may require a filter; refer to product labeling. Do not use with ethanol or protein hydrolysates (precipitation may form).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130891\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypovolemia:</b> Plasma volume expansion and maintenance of cardiac output in the treatment of certain types of shock or impending shock; adult respiratory distress syndrome (ARDS), acute/severe nephrosis, hemolytic disease of the newborn; cirrhotic ascites (prevention of central volume depletion after paracentesis); ovarian hyperstimulation syndrome (treatment); plasma volume exchange (replacement fluid); unless the condition responsible for hypoproteinemia can be corrected, albumin can provide only symptomatic relief or supportive treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25720703\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cirrhosis (in combination with diuretics to facilitate diuresis); Spontaneous bacterial peritonitis (treatment); Volume expansion in dehydrated, mildly hypotensive patients with cirrhosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130929\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albuminar-25 (albumin) may be confused with Privigen (immune globulin) due to similar packaging</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Albutein may be confused with albuterol </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Buminate may be confused with bumetanide</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130882\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac failure (precipitation), edema, hypertension, hypotension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypervolemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130894\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to albumin or any component of the formulation; severe anemia, heart failure; patients at risk of volume overload (eg, patients with renal insufficiency, severe anemia, stabilized chronic anemia, or heart failure); dilution with sterile water for injection (may cause hemolysis or acute renal failure)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130880\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe allergic or anaphylactic reaction may occur. Discontinue immediately and manage appropriately if allergic or anaphylactic reactions are suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coagulation abnormality: Large replacement volumes may result in coagulation abnormality. Monitor and replete with blood constituents if indicated. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Large replacement volumes may result in electrolyte imbalance. Monitor electrolytes and replace or maintain as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemodynamic effects: Cardiac or respiratory failure, renal failure, or increasing intracranial pressure can occur; closely monitor hemodynamic parameters in all patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypervolemia/hemodilution: Use with caution in conditions where hypervolemia and its consequences or hemodilution may increase the risk of adverse effects (eg, heart failure, pulmonary edema, hypertension, hemorrhagic diathesis, esophageal varices). Adjust rate of administration per hemodynamic status and solution concentration; monitor closely with rapid infusions. Avoid rapid infusions in patients with a history of cardiovascular disease (may cause circulatory overload and pulmonary edema). Discontinue at the first signs of cardiovascular overload (eg, headache, dyspnea, jugular venous distention, rales, abnormal elevations in systemic or central venous blood pressure). All patients should be observed for signs of hypervolemia, such as pulmonary edema. Monitor blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Critical illness: In patients with increased microvascular permeability (eg, sepsis,  trauma, burn), the translocation of fluid from the interstitial compartment to the intravascular compartment may decrease due to increased albumin in the interstitial space. Furthermore, in extreme microvascular permeability states, administration of albumin (or other colloids) may increase the net flux of fluid into the interstitial space reducing intravascular volume and precipitating edematous states (eg, pulmonary edema) (Roberts, 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; protein load may exacerbate or precipitate encephalopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; protein load may precipitate azotemia. Patients with chronic renal insufficiency receiving albumin solution may be at risk for accumulation of aluminum and potential toxicities (eg, hypercalcemia, vitamin D refractory osteodystrophy, anemia, severe progressive encephalopathy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sodium restricted patients: Use with caution in those patients for whom sodium restriction is necessary. Albumin 5% and 25% solutions contain 130 to 160 mEq/L sodium and are considered isotonic with plasma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aluminum: The parenteral product may contain aluminum (Kelly, 1989); toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dilution: Do not dilute 5% albumin with sterile water for injection (may result in hemolysis and/or renal failure).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Latex: Packaging may contain natural latex rubber.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298693\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130884\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9376&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130886\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13334387\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Available data is insufficient to recommend use of albumin to reduce the risk of ovarian hyperstimulation syndrome (ASRM 2016). Use for other indications may be considered in pregnant women when contraindications to nonprotein colloids exist (Liumbruno 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13334388\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Endogenous albumin is found in breast milk. The manufacturer recommends that caution be exercised when administering albumin to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2885289\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Some products may contain potassium and/or sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130888\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor electrolytes, hemoglobin/hematocrit, and urine output regularly; monitor hemodynamic parameters, blood pressure, heart rate, central venous pressure, pulmonary artery occlusion pressure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130879\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Provides increase in intravascular oncotic pressure and causes mobilization of fluids from interstitial into intravascular space</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45653130\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;\">Half-life: 15 to 20 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322967\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Albuked 25 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $60.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Albuked 5 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (250 mL): $57.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Albumin Human Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (250 mL): $83.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $68.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Albuminar-25 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $112.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Albuminar-5 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (250 mL): $112.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Albutein Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (250 mL): $62.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $59.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Buminate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (250 mL): $131.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (20 mL): $131.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Flexbumin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (250 mL): $69.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $69.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Human Albumin Grifols Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $108.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Plasbumin-25 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25% (50 mL): $59.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Plasbumin-5 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5% (50 mL): $39.12</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130897\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acebumin (PE);</li>\n      <li>Alba (IN);</li>\n      <li>Albapure (ID, TW);</li>\n      <li>Albiomin (TH);</li>\n      <li>Albotein (IT);</li>\n      <li>Albuman (IS, MT);</li>\n      <li>Albumar (MX);</li>\n      <li>Albumax (PH);</li>\n      <li>Albumer (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Albumex (AU, NZ);</li>\n      <li>Albumex 20 (HK);</li>\n      <li>Albumin 5% (CH);</li>\n      <li>Albumin 5% Human (DE);</li>\n      <li>Albumin Human Salzarm 25% (DE);</li>\n      <li>Albumina Humana (BR, CU);</li>\n      <li>Albuminar (BR, ID, IL, PH, VN);</li>\n      <li>Albuminar 25 (TH);</li>\n      <li>Albuminativ (AT, SE);</li>\n      <li>Albuminative (QA, SA);</li>\n      <li>Albunate (MX);</li>\n      <li>Albunorm (BG, HR, HU, IE, LU, LV, NO, PH, RO, SI, UA);</li>\n      <li>Alburel (PH);</li>\n      <li>Alburex (CO, CY);</li>\n      <li>Alburx (CN);</li>\n      <li>Albusol (ZA);</li>\n      <li>Albutein (AE, BH, HR, LB, LK, PH, SA, VN);</li>\n      <li>Albutein 25% (BR, CN, HK);</li>\n      <li>Biseko (PL);</li>\n      <li>Buminate (SA);</li>\n      <li>Buminate 25% (HK, PH);</li>\n      <li>Cealb (AE);</li>\n      <li>Flexbumin (CZ, IE, LV, SK, VN);</li>\n      <li>Human Albumin 25% (DE);</li>\n      <li>Human Albumin 5% (DE);</li>\n      <li>Kedrialb (PH);</li>\n      <li>Octalbin (DK, ES, FI, ID, MX);</li>\n      <li>Plasbumin (AE, ID, LB, SG);</li>\n      <li>Seralbumin (CR, DO, GT, HN, PA, PY, SV);</li>\n      <li>Seroalbumin (PH);</li>\n      <li>SRK (CH);</li>\n      <li>Vialebex (FR);</li>\n      <li>Volumin (IN);</li>\n      <li>Zenalb (GR, ID, MT, SG, TH, VN);</li>\n      <li>Zenalb 20 (CO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abd Elaal MM, Zaghloul SG, Bakr HG, et al. Evaluation of different therapeutic approaches for spontaneous bacterial peritonitis. <i>Arab J Gastroenterol</i>. 2012;13(2):65-70. doi: 10.1016/j.ajg.2012.06.003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/22980594/pubmed\" target=\"_blank\" id=\"22980594\">22980594</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albuked 5 (albumin [human]) [prescribing information]. Cambridge, MA: Kedrion Biopharma Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albuked 25 (albumin [human]) [prescribing information]. Cambridge, MA: Kedrion Biopharma Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albuminar-25 (albumin [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    AlbuRx 5 (albumin [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    AlbuRx 25 (albumin [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albutein 5 (albumin [human]) [prescribing information]. Clayton, NC: Grifols Therapeutics Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Albutein 25 (albumin [human]) [prescribing information]. Clayton, NC: Grifols Therapeutics Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR &sect;201.323.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Thoracic Society (ATS), &ldquo;Evidence-Based Colloid Use in the Critically Ill: American Thoracic Society Consensus Statement,&rdquo; <i>Am J Respir Crit Care Med</i>, 2004, 170(11):1247-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/15563641/pubmed\" target=\"_blank\" id=\"15563641\">15563641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. <i>Hepatology</i>. 1999;29(6):1690-1697.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/10347109/pubmed\" target=\"_blank\" id=\"10347109\">10347109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Belver J, Mu&ntilde;oz EA, Ballesteros A, et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. <i>Hum Reprod</i>. 2003;18(11):2283-2288.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/14585874/pubmed\" target=\"_blank\" id=\"14585874\">14585874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. <i>Hepatology</i>. 2012;55(4):1172-1181.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/22095893/pubmed\" target=\"_blank\" id=\"22095893\">22095893</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brierley J, Carcillo JA, Choong K, et al, &ldquo;Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,&rdquo; <i>Crit Care Med</i>, 2009, 37(2):666-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/19325359/pubmed\" target=\"_blank\" id=\"19325359\">19325359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Budev MM, Arroliga AC, Falcone T. Ovarian hyperstimulation syndrome. <i>Crit Care Med</i>. 2005;33(10 Suppl):S301-S306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/16215351/pubmed\" target=\"_blank\" id=\"16215351\">16215351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caraceni P, Angeli P, Prati D, et al; Italian Association for the Study of the Liver (AISF); Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. <i>Blood Transfus</i>. 2016;14(1):8-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/26820615 /pubmed\" target=\"_blank\" id=\"26820615 \">26820615 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cavallin M, Kamath PS, Merli M, et al; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. <i>Hepatology</i>. 2015;62(2):567-574.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/25644760/pubmed\" target=\"_blank\" id=\"25644760\">25644760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. <i>Hepatology</i>. 2016;63(3):983-992.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/26659927/pubmed\" target=\"_blank\" id=\"26659927\">26659927</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Hemolysis Associated With 25% Human Albumin Diluted With Sterile Water - United States, 1994-1998,&rdquo; <i>MMWR</i>, March 5, 1999, 48(8):157-9. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00056596.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00056596.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/10079061/pubmed\" target=\"_blank\" id=\"10079061\">10079061</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Finfer S, Bellomo R, Boyce N, et al, &ldquo;A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit. SAFE Study Investigators,&rdquo; <i>N Engl J Med</i>, 2004, 350(22):2247-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/15163774/pubmed\" target=\"_blank\" id=\"15163774\">15163774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flexbumin 5% (albumin human) [prescribing information]. Westlake Village, CA: Baxter Healthcare Corporation; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flexbumin 25% (albumin human) [prescribing information]. Westlake Village, CA: Baxter Healthcare Corporation; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fortin PM, Bassett K, Musini VM. Human albumin for intradialytic hypotension in haemodialysis patients. <i>Cochrane Database Syst Rev.</i> 2010;(11):CD006758.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/21069691/pubmed\" target=\"_blank\" id=\"21069691\">21069691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jee BC, Suh CS, Kim YB, et al. Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis. <i>Gynecol Obstet Invest</i>. 2010;70(1):47-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/20173327/pubmed\" target=\"_blank\" id=\"20173327\">20173327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly AT, Short BL, Ranis TC, May JC, Progar JJ. Aluminum toxicity and albumin. <i>ASAIO Trans</i>. 1989;35(3):674-676.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/2597561/pubmed\" target=\"_blank\" id=\"2597561\">2597561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knoll GA, Grabowski JA, Dervin GF, et al. A randomized, controlled trial of albumin versus saline for the treatment of intradialytic hypotension. <i>J Am Soc Nephrol</i>. 2004;15(2):487-492.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/14747397/pubmed\" target=\"_blank\" id=\"14747397\">14747397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liumbruno GM, Bennardello F, Lattanzio A, et al, &quot;Recommendations for the Use of Albumin and Immunoglobulins,&quot; <i>Blood Transfus</i>, 2009, 7(3):216-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/19657486/pubmed\" target=\"_blank\" id=\"19657486\">19657486</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maitland K, Kiguli S, Opoka RO, et al, &quot;Mortality After Fluid Bolus in African Children With Severe Infection,&quot; <i>N Engl J Med</i>, 2011, 364(26):2483-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/21615299/pubmed\" target=\"_blank\" id=\"21615299\">21615299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mart&iacute;n-Llah&iacute; M, P&eacute;pin MN, Guevara M, et al; TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. <i>Gastroenterology</i>. 2008;134(5):1352-1359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/18471512/pubmed\" target=\"_blank\" id=\"18471512\">18471512</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moore KP, Wong F, Gines P, et al, &ldquo;The Management of Ascites in Cirrhosis: Report on the Consensus Conference of the International Ascites Club,&rdquo; <i>Hepatology</i>, 2003, 38(1):258-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/12830009/pubmed\" target=\"_blank\" id=\"12830009\">12830009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ortega R, Gin&egrave;s P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. <i>Hepatology</i>. 2002;36(4 Pt 1):941-948.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/12297842/pubmed\" target=\"_blank\" id=\"12297842\">12297842</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plasbumin-5 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plasbumin-25 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. <i>Fertil Steril</i>. 2016;106(7):1634-1647. doi: 10.1016/j.fertnstert.2016.08.048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/27678032/pubmed\" target=\"_blank\" id=\"27678032\">27678032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts JS and Bratton SL, Colloid volume expanders. Problems, pitfalls, and possibilities. Drugs, 1998, 55(5):621-630.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/9585860/pubmed\" target=\"_blank\" id=\"9585860\">9585860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16552809\"></a>Romanelli RG1, La Villa G, Barletta G. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. <i>World J Gastroenterol</i>. 2006;12(9):1403-1407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/16552809/pubmed\" target=\"_blank\" id=\"16552809\">16552809</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Runyon BA. Management of adult patients with ascites due to cirrhosis: update 2012. Alexandria, VA: American Association for the Study of Liver Diseases; 2012. http://www.aasld.org/sites/default/files/guideline_documents/AASLDPracticeGuidelineAsciteDuetoCirrhosisUpdate2012Edition4_.pdf. Accessed May 6, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sort P, Navasa M, Arroyo V, et al, &ldquo;Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis,&rdquo; <i>N Engl J Med</i>, 1999, 341(6):403-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/10432325/pubmed\" target=\"_blank\" id=\"10432325\">10432325</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    UHC Clinical Practice Advancement Center. Technology assessment: albumin, nonprotein colloid, and crystalloid solutions. Oak Brook, IL: University HealthSystem Consortium; May 2000.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vermeulen LC Jr, Ratko TA, Erstad BL, et al. A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. <i>Arch Intern Med</i>. 1995;155(4):373-379.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/7848020/pubmed\" target=\"_blank\" id=\"7848020\">7848020</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Papadimas I, Tarlatzis BC. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. <i>Fertil Steril</i>. 2011;95(1):188-196.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/albumin-solution-drug-information/abstract-text/20579987/pubmed\" target=\"_blank\" id=\"20579987\">20579987</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9376 Version 146.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F130903\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F130904\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F130921\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F130906\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F130915\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F130907\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15671332\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671333\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F130890\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F130876\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F130892\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F130891\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25720703\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F130929\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F130882\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F130894\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F130880\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298693\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F130884\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F130886\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13334387\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13334388\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F2885289\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F130888\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F130879\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F45653130\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322967\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F130897\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9376|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=albumin-solution-patient-drug-information\" class=\"drug drug_patient\">Albumin solution: Patient drug information</a></li><li><a href=\"topic.htm?path=albumin-solution-pediatric-drug-information\" class=\"drug drug_pediatric\">Albumin solution: Pediatric drug information</a></li></ul></div></div>","javascript":null}